Editas Medicine (EDIT) to Release Quarterly Earnings on Monday

Editas Medicine (NASDAQ:EDIT) is anticipated to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Editas Medicine to post earnings of ($0.30) per share and revenue of $5.8840 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 12:30 PM ET.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.21. Editas Medicine had a negative return on equity of 389.73% and a negative net margin of 395.02%.The business had revenue of $24.74 million for the quarter, compared to analysts’ expectations of $8.77 million. On average, analysts expect Editas Medicine to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Editas Medicine Stock Up 2.9%

Shares of EDIT stock traded up $0.09 during mid-day trading on Monday, hitting $2.99. 370,333 shares of the company’s stock were exchanged, compared to its average volume of 1,692,604. Editas Medicine has a fifty-two week low of $1.29 and a fifty-two week high of $4.54. The stock has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $2.49. The stock has a market cap of $292.26 million, a price-to-earnings ratio of -1.58 and a beta of 2.14.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Robert W. Baird set a $6.00 target price on Editas Medicine in a research report on Monday, March 9th. Chardan Capital reaffirmed a “buy” rating and issued a $3.50 target price on shares of Editas Medicine in a research report on Monday, March 9th. TD Cowen reaffirmed a “buy” rating on shares of Editas Medicine in a research report on Monday, March 9th. JonesTrading raised Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Tuesday, March 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Editas Medicine in a research report on Monday, April 20th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.30.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in EDIT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Editas Medicine by 122.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Editas Medicine by 288.5% during the first quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock worth $869,000 after purchasing an additional 558,567 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Editas Medicine by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,964,298 shares of the company’s stock worth $4,323,000 after purchasing an additional 20,521 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Editas Medicine by 15.2% during the second quarter. JPMorgan Chase & Co. now owns 1,065,722 shares of the company’s stock worth $2,345,000 after purchasing an additional 140,916 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Editas Medicine by 500.0% during the second quarter. Bridgeway Capital Management LLC now owns 120,000 shares of the company’s stock worth $264,000 after purchasing an additional 100,000 shares in the last quarter. 71.90% of the stock is owned by hedge funds and other institutional investors.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.